News Nuvalent, Inc.

Equities

NUVL

US6707031075

Market Closed - Nasdaq Other stock markets 01:30:00 03/05/2024 am IST			5-day change	1st Jan Change
72.49 ^USD	+2.60%		+9.72%	-1.49%

01/05	Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing	MT
17/04	Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing	02/05	MT
Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	18/04	MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target	17/04	MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing	11/04	MT
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing	01/04	MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69	01/04	MT
Nuvalent Insider Sold Shares Worth $3,032,528, According to a Recent SEC Filing	28/03	MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing	26/03	MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating	28/02	MT
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results	28/02	AQ
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520	28/02	AQ
Nuvalent's Non-Small Cell Lung Cancer Drug Candidate Gets FDA Breakthrough Therapy Designation	27/02	MT
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02	CI
Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105	23/02	MT
Nuvalent Starts Phase 2 Part of Clinical Trial of Potential Lung Cancer Treatment	12/02	MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating	12/02	MT
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors	12/02	CI
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nuvalent, Inc.

Equities

NUVL

US6707031075

Summary

Filters